Brian Hu, MD
Urology · Loma Linda, CANPI 1003073883
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,775 of the $74,153 with a category attached, or 71.2%. Urogen Pharma, Inc. accounts for 90.7% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $49,431, more than ten times the $675 reported in 2019. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $686.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$67K
- Ferring Pharmaceuticals Inc.$4K
- Intuitive Surgical$577
- EDAP Technomed Inc$539
- Dendreon Pharmaceuticals LLC$438
- Astellas Pharma US Inc$239
- plus $1K from 18 others
Across 132 payments — averaging $1870.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$113K
- Janssen Research & Development, LLC$89K
- QED Therapeutics, Inc.$45K
What the payments were for
- Consulting fees$8,08311%
- Speaking & faculty fees$52,77571%
- Grants$120%
- Travel & lodging$7,97211%
- Food & beverage$5,2667%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 61 | $67,261 |
| Ferring Pharmaceuticals Inc. | 7 | $3,928 |
| Intuitive Surgical | 3 | $577 |
| EDAP Technomed Inc | 4 | $539 |
| Dendreon Pharmaceuticals LLC | 6 | $438 |
| Astellas Pharma US Inc | 3 | $239 |
| Procept Biorobotics Corporation | 1 | $144 |
| QED Therapeutics, Inc. | 1 | $135 |
| Myovant Sciences GmbH | 1 | $125 |
| Merck | 3 | $113 |
| Immunitybio, Inc. | 1 | $102 |
| Janssen Research & Development, LLC | 2 | $100 |
| Photocure Inc | 1 | $93 |
| Bayer | 1 | $57 |
| AbbVie | 4 | $54 |
| Antares Pharma, Inc. | 1 | $44 |
| Pfizer | 1 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Cook Medical LLC | 1 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Pelvital USA, Inc. | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $17 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZUSDURI$44,133
- JELMYTO$20,920
- ADSTILADRIN$3,793
- Da Vinci Surgical System$500
- FOCAL ONE$417
- PROVENGE$245
- AquaBeam Robotic System$144
- ORGOVYX$125
- PADCEV$115
- ANKTIVA$102
How this compares
$74,153 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $9,843 |
| GemtesaVibegron | 12 | $5,739 |
| Tamsulosin Hcl | 147 | $1,401 |
| Finasteride | 70 | $622 |
| Ciprofloxacin Hcl | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $239 | $9,84313 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $5,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Loma Linda
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.